(Q32094)
Statements
Oral HPV infection is the main risk factor for the development of oropharyngeal carcinoma. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
Men who have sex with men (MSM), especially if living with HIV (PLWH), are at increased risk of infection and consequently of cancer development. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
Aim of this study is to evaluate the impact of nonavalent vaccine on oral HPV infection in a cohort of MSM and transgender women (TGW). (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
This prospective study included all MSM and TGW who started nonavalent HPV vaccination from May 2019 to September 2021. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
Oral rinse was collected before each vaccine administration and after six months of follow up. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
Descriptive statistics were used. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
Kaplan Meier probability curves and Cox regression models for HPV acquisition and clearance were calculated. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
The analysis included 211 individuals (202 MSM and 9 TGW). (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
PLWH were 138 (65.4%). (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
Baseline oral rinse was positive in 30 subjects (14.2%). (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
Positivity rate did not change over time (p = 0.742), even when restricting the analysis only to high-risk genotypes (p = 0.575) and to genotypes covered by vaccine (p = 0.894). (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
The risk to acquire HPV infection was 12.8% at one year and 33.4% at two years after vaccination. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
The probability to clear the infection was 67.6% at one year and 87.9% at two years. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
HIV infection had no impact on vaccine efficacy. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
Age above 45 years was the only factor associated to HPV acquisition (aHR 4.06, 95% CI 1.03-15.98, p = 0.045). (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
Prevalence of oral HPV infection was higher in PLWH, but HIV had no impact on viral clearance or acquisition after vaccination. (English)
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. (English)
2024
Roberto (English)
Rossotti (English)
R
Alice (English)
Nava (English)
A
Chiara (English)
Baiguera (English)
C
Luca (English)
Baldassari (English)
L
Maria Cristina (English)
Moioli (English)
MC
Diana (English)
Fanti (English)
D
Federico (English)
D'Amico (English)
F
Daniele (English)
Calzavara (English)
D
Simona (English)
Bossolasco (English)
S
Andrea Marco (English)
Tamburini (English)
AM
Diana (English)
Canetti (English)
D
Nicholas Brian (English)
Bana (English)
NB
Massimo (English)
Cernuschi (English)
M
Chiara (English)
Vismara (English)
C
Massimo (English)
Puoti (English)
M
27 August 2024
27 August 2024